UCI Beall Applied Innovation

Research Translation Group

Research Translation Group

Available Technologies

Contact Us

Request Information

Permalink

Combination Therapy for Glaucoma

Tech ID: 33937 / UC Case 2024-966-0

BRIEF DESCRIPTION

An innovative small molecules therapy that significantly lowers intraocular pressure in glaucoma patients, offering neuroprotection and addressing trabecular meshwork fibrosis.

FULL DESCRIPTION

This technology encompasses a synergistic combination of sodium 4-phenylbutyrate (PBA) and Tauroursodeoxycholic acid (TUDCA) for the treatment of glaucoma. This approach not only lowers intraocular pressure (IOP) more effectively than current medications but also acts as a direct neuroprotectant and counters fibrosis in the trabecular meshwork (TM), potentially increasing the success rate of IOP-lowering surgeries and interventions.

SUGGESTED USES

- >> Primary and adjunctive therapy for all forms of glaucoma.
- >> Preventive treatment for high-risk individuals to protect against neuronal loss.
- » Complementary therapy to enhance the success rate of IOP-lowering surgeries and devices.

ADVANTAGES

- » Significantly lowers IOP by up to 40%, outperforming current glaucoma drugs.
- » Reduces IOP by targeting trabecular meshwork pathology in glaucoma.
- >> Offers direct neuroprotection to prevent neuronal loss associated with glaucoma.
- » Addresses and potentially reverses trabecular meshwork fibrosis, a common cause of surgical failure in glaucoma treatment.
- **»** Can be used alone or in conjunction with existing IOP-lowering medications, offering a versatile treatment option.
- **»** Based on FDA-approved molecules for other conditions, potentially easing the regulatory pathway for glaucoma treatment.
- >> Excellent proof-of-concept data in preclinical mouse and human models of glaucoma.

PATENT STATUS

Patent Pending

CONTACT

Patricia H. Chan patricia.chan@uci.edu tel: 949-824-6821.



OTHER INFORMATION

KEYWORDS

trabecular meshwork, small molecule, glaucoma

CATEGORIZED AS

» Medical

Disease:Ophthalmology andOptometry

>> Therapeutics

RELATED CASES

2024-966-0

UCI Beall Applied Innovation

5270 California Avenue / Irvine,CA 92697-7700 / Tel: 949.824.2683



© 2025, The Regents of the University of California Terms of use Privacy Notice